Another randomized controlled trial compared cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6) to chemotherapy without the targeted agent in patients with unresectable liver metastases from CRC harboring wild-type KRAS. The gene discussed is KRAS; the disease is colorectal carcinoma.